ID-JPL934 for Abnormal Bowel Movement
ID-JPL934 for Abnormal Bowel Movement
Probiotics, which are part of the human body, are microorganisms, which are known to have
 beneficial effects when consumed in a certain amount, and have the function of controlling
 intestinal flora and inhibiting inflammation. Recently, probiotics have received much
 attention in the treatment of hypersensitivity syndrome. The aim of this study was to
 investigate the effect of probiotic strains, ID-JPL934, in the diagnosis of irritable bowel
 syndrome.

 Overall satisfaction with improvement of bowel habits such as diarrhea and constipation as
 well as abdominal discomfort and abdominal discomfort in the group receiving ID-JPL934
 capsules (test food group or test group) and control group (control food group or control
 group) (0-10 point visual analogue scale) for each symptom before and after ingestion to
 evaluate the degree of improvement of the symptoms. The purpose of this study was to
 investigate the relationship between bacterial composition changes in the stool and the
 improvement of symptoms in the patients before and after ingestion.
Inclusion Criteria:

 1. Korean men and women aged over 19 and 80

 2. Adults with the following criteria (1) If the symptoms are relieved by bowel movements
 and changes in the number of bowel movements with less than two stomach complaints or
 stomach complaints every three months (2), these two forms of bowel movements have
 started (3)

 3. Methodological-fractive women or fertile women who are negative during pregnancy
 diagnostic tests (urine or seron- hCG). An appropriate method of birth control (e.g.,
 " oral contraceptive " or bi-fertility) during an examination

 4. People who have no problems in their nerves and mental systems and who can make their
 own doctors clear

 5. The person who agreed in writing to this test

 Exclusion Criteria:

 1. Persons with hypersensitivity to probiotics

 2. Pregnant or lactating women

 3. People who have received other clinical trial drugs within the first 3 months of visit
 1. However, in the case of lactic acid bacteria preparation, the test can be taken
 after a two week absence period.

 4. A person who believes that the participant is in a condition or situation in which
 participation in the clinical trial may be hazardous to the participant,

 5. Patients with severe congestive heart failure or severe angina

 6. If the patient is diagnosed as having urticaria or immunosuppression

 7. Patients who are taking or taking medications (formulants, lactic acid bacteria) that
 may affect the test food, probiotics, or during the test period. However, if you are
 taking the drug, you can take the test after two weeks of abstinence.

 8. If the systolic blood pressure measured at Visit 1 is greater than 160 mmHg or
 diastolic blood pressure is greater than 100 mmHg and hypertension is not controlled
 regardless of whether the medication is administered or not.

 9. Patients with uncontrolled endocrine diseases (such as diabetes), metabolic diseases
 (eg secondary hyperlipidemia) or hypothyroidism (subjects with a history of
 hypothyroidism) should receive a stable thyroid hormone supplement for at least 4
 weeks prior to visit 1 If you are on therapy, you can participate in this test only if
 the TSH level measured at Visit 2 is within the normal range.)

 10. If kidney function is impaired at visit 1 (creatinine> 2.0 mg / dL) or nephrotic
 syndrome is observed

 11. If the cancer has developed within the past 5 years (unless it is determined to be
 cured)

 12. If there is a history of mental instability and drug / alcohol abuse within the past 5
 years, or if major psychiatric illnesses are not adequately controlled and stabilized
 by medication

 13. Visits 1 If you have taken mental nerve agents within the previous 3 months

 14. If you take a systemic steroid preparation within 1 month before visit 1

 15. Patients who underwent abdominal surgery except for appendectomy, hernia surgery, and
 cesarean section

 16. People who are suffering from hypersensitivity syndrome in the ROME Ⅲ standard

 17. Any person deemed inappropriate for the judgment of the clinician